Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742091 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT01742091 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 59 participants.
The verdict
NCT01742091, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes the body to get rid of it, the overall effect of the study drug on the body, and whether antibodies to the study drug are formed.
Interventions
- DRUG LY2541546 - IV
- DRUG LY2541546 - SC
- DRUG Placebo - IV
- DRUG Placebo - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742091
The ClinicalTrials.gov registry entry for NCT01742091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LY2541546 - IV is the first listed.
NCT01742091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742091 about?
NCT01742091 is a clinical study titled "A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women". The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body...
What is the current status of trial NCT01742091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-09. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01742091?
The interventions under investigation include: LY2541546 - IV (DRUG), LY2541546 - SC (DRUG), Placebo - IV (DRUG), Placebo - SC (DRUG).
Who is sponsoring clinical trial NCT01742091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.